1-Amino-9,10-dioxo-4-[(4-sulfamoylphenyl)amino]-9,10-dihydroanthracene-2-sulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1-Amino-9,10-dioxo-4-[(4-sulfamoylphenyl)amino]-9,10-dihydroanthracene-2-sulfonic acid
• 英文别名: 1-amino-9,10-dioxo-4-(4-sulfamoylanilino)anthracene-2-sulfonic acid
• 化学式: C₂₀H₁₅N₃O₇S₂
• 分子量: 473.5
• InChiKey: RRARWTAYDLOASH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  204
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME
  申请人：Japan Science and Technology Agency

  公开号：EP1535629A1

  公开（公告）日：2005-06-01

  There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.

  提供了一种用于治疗或预防脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤的化合物及其筛选方法。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑损伤区域的小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区域周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防前列腺素 D2 参与的脑损伤。此外，还提供了一种利用大量表达人造血前列腺素 D 合酶的转基因小鼠检测这些药物的方法。
• Drugs for improving prognosis of brain injury
  申请人：Japan Science and Technology Agency

  公开号：EP1598065A2

  公开（公告）日：2005-11-23

  A compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease. The compound comprises an antagonist for the prostaglandin D receptor as an effective ingredient. Brain injury in which prostaglandin D2 is a factor is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area.

  一种化合物，用于治疗或预防由脑血管疾病、脑变性疾病和脱髓鞘疾病等疾病引起的脑损伤。该化合物的有效成分包括前列腺素 D 受体拮抗剂。 通过抑制脑血管疾病、脑变性疾病或脱髓鞘疾病等疾病在脑区小胶质细胞或巨噬细胞中诱导的造血前列腺素 D 合成酶，或通过抑制损伤区周围星形胶质细胞中表达的前列腺素 D 受体的活化，治疗或预防以前列腺素 D2 为因素的脑损伤。
• Method for treating myolytic disease and method for screening antimyolytic agent
  申请人：Urade Yoshihiro

  公开号：US20050272767A1

  公开（公告）日：2005-12-08

  An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.

  本发明的目的是提供一种能够预防或改善肌肉溶解性疾病（如肌肉萎缩症）的方法。本发明的目的可以通过以下方法来实现：向需要的患者施用有效剂量的造血前列腺素 D 合酶（H-PGDS）抑制剂或前列腺素 D 受体拮抗剂。本发明还提供了一种利用人体H-PGDS过表达转基因小鼠筛选能够防止肌溶解性疾病进展和改善肌溶解性疾病的化合物的方法。
• METHOD FOR DIAGNOSIS OF SEVERITY AND PREDICTION OF RECURRENCE IN EOSINOPHILIC INFLAMMATORY DISEASE
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP1882937B1

  公开（公告）日：2012-02-22
• JP2004002248A
  申请人：——

  公开号：JP2004002248A

  公开（公告）日：2004-01-08